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Abstract: Certain endogenous bile acids have been proposed as potential therapies for ameliorating
Alzheimer’s disease (AD) but their role, if any, in the pathophysiology of this disease is not currently
known. Given recent evidence of bile acids having protective and anti-inflammatory effects on the
brain, it is important to establish how AD affects levels of endogenous bile acids. Using LC-MS/MS,
this study profiled 22 bile acids in brain extracts and blood plasma from AD patients (n = 10) and
age-matched control subjects (n = 10). In addition, we also profiled brain/plasma samples from
APP/PS1 and WT mice (aged 6 and 12 months). In human plasma, we detected significantly lower
cholic acid (CA, p = 0.03) in AD patients than age-matched control subjects. In APP/PS1 mouse plasma
we detected higher CA (p = 0.05, 6 months) and lower hyodeoxycholic acid (p = 0.04, 12 months) than
WT. In human brain with AD pathology (Braak stages V-VI) taurocholic acid (TCA) were significantly
lower (p = 0.01) than age-matched control subjects. In APP/PS1 mice we detected higher brain
lithocholic acid (p = 0.05) and lower tauromuricholic acid (TMCA; p = 0.05, 6 months). TMCA was
also decreased (p = 0.002) in 12-month-old APP/PS1 mice along with 5 other acids: CA (p = 0.02),
β-muricholic acid (p = 0.02), Ω-muricholic acid (p = 0.05), TCA (p = 0.04), and tauroursodeoxycholic
acid (p = 0.02). The levels of bile acids are clearly disturbed during the development of AD pathology
and, since some bile acids are being proposed as potential AD therapeutics, we demonstrate a method
that can be used to support work to advance bile acid therapeutics.
Keywords: bile acids; metabolomics; Alzheimer’s disease; metabolites
1. Introduction
Bile acids play complex roles in cell signalling and immunomodulation, and bile acid receptors are
considered therapeutic targets for various metabolic diseases [1,2]. Primary bile acids are synthesized
in liver cells through the oxidation of cholesterol. They play an important role in lipid digestion. The
oxidized cholesterol metabolites, oxysterols, activate nuclear receptors (LXRs) which are implicated
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in neurodegenerative disease [3,4]. Greenberg et al. observed a trend of increased glycocholic acid
(GCA), glycodeoxycholic acid (GDCA), and glycochenodeoxycholic acid (GCDCA) in mild cognitive
impairment (MCI) and AD, although none of these reached statistical significance [5]. Just recently, it
has been reported that the blood plasma levels of deoxycholic acid (DCA), lithocholic acid (LCA), and
GDCA acids are significantly elevated in patients with amnestic MCI and AD [6]. Similarly, significant
increases in the levels of the secondary bile acid glycoursodeoxycholic acid (GUDCA) have been
described in the plasma of AD patients [7].
Considerably fewer studies have examined the levels of bile acids in the brain, but the occurrence
of these molecules has been reported [8–10]. For example, cholic acid (CA), chenodeoxycholic acid
(CDCA), and DCA have been detected in rat brain [8]. The levels of CDCA in the brain were
approximately 30 times greater than those in serum [8]. Some of the underlying biochemistry
has been established. For example, the conversion of 3β-hydroxychol-5-en-24-oic acid to CDCA
via 3β,7α-dihydroxychol-5-en-24-oic acid and 7α-hydroxy-3-oxochol-4-en-24-oic acid has been
demonstrated in the rat brain [9].
There also appears to be some scope to apply bile acids as potential AD therapeutics [11,12]. One
line of inquiry is based upon the strong modulatory effect of some bile acids on apoptosis and the
observation that tauroursodeoxcholic acid (TUDCA) can inhibit neuronal apoptosis in a number of
experimental models of neurodegenerative disease. TUDCA appears to be neuroprotective in AD,
Huntington’s disease (HD), and Parkinson’s disease (PD) [11]. In models of AD pathology TUDCA
reduces p53-mediated apoptosis in AD mutant neuroblastoma cells [11]. Systemic administration of
TUDCA significantly reduces striatal neuropathology in the R6/2 transgenic HD mouse [12]. TUDCA
improves the survival and function of nigral transplants in a rat model of Parkinson’s disease [13].
Furthermore, in an animal model of acute neuro-inflammation TUDCA has a ‘triple anti-inflammatory’
effect on the glial cells [14]. It reportedly reduces glial cell activation, reduces microglial cell migratory
capacity, and lowers expression of chemoattractants and vascular adhesion proteins [14].
The rapid development of metabolomics as a discipline now makes it much more feasible to
profile the wide range of bile acid species which occur physiologically. A range of metabolomic and
lipidomic investigations of human AD and AD-like pathology have been undertaken. For example,
studies have undertaken non-targeted profiling of polar metabolites [15–18] and non-polar (lipid)
metabolites [19], and there has also been targeted profiling of fatty acids [20,21], phospholipids [7,22],
and steroids [23]. However, no study as far as we are aware has focused exclusively on the profiling
of bile acids. The fact that some non-targeted metabolomic studies have reported disturbed levels of
some bile acids in AD is encouraging, but it should be pointed out that, to date, there has not been
any focused examination of how AD pathology affects brain bile acids. Measuring changes in brain
levels would seem to be an appropriate issue to address, given the observed protective effects of these
molecules (i.e., TUDCA) on the brain.
This study profiled a range of conjugated and unconjugated C24 bile acids across a range of AD
samples. We sampled blood plasma from AD patients and cognitively normal aged-matched control
subjects, as well as neocortical tissue from pathologically confirmed cases of AD and age-matched
controls. We also sampled blood plasma and brain samples from APP/PS1 mice and WT littermates at
both 6 months and 12 months of age. Our hypothesis was that the bile acid system is affected by the
development of AD pathology and the aim was to determine specific bile acid changes.
2. Results
2.1. Bile Acid Levels in Human Plasma
Of the 22 bile acids screened, 15 were quantifiable in the human plasma samples analysed. Only
CA was significantly affected in cases of AD (Table 1). In AD patients CA was significantly lower
(947 ± 483 nM vs. 156 ± 74 nM; p = 0.03).
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Table 1. Bile acid levels in human plasma.
Bile Acid Control (n = 10) AD (n = 10) p-Value ROC
CA 947 ± 483 156 ± 74 0.03 0.77
CDCA 2781 ± 2329 312.2 ± 147 0.14 0.62
DCA 938 ± 375 638 ± 212 0.28 0.55
GCA 281 ± 76 364 ± 67 0.14 0.63
GCDCA 1218 ± 261 1118 ± 162 0.47 0.56
GDCA 625 ± 125 831 ± 199 0.31 0.58
GLCA 42 ± 12 42 ± 10 0.39 0.53
GLCAS 484 ± 99 687 ± 126 0.14 0.67
GUDCA 141 ± 40 170 ± 84 0.41 0.54
HDCA <LOD <LOD - -
LCA 63 ± 19 44 ± 10 0.27 0.63
α-MCA <LOD <LOD - -
β-MCA <LLOQ <LLOQ 0.08 -
Ω-MCA 39 ± 18 15 ± 9 0.25 0.71
TCA 39 ± 12 87 ± 25 0.09 0.72
TCDCA 147 ± 39 184 ± 56 0.38 0.51
TDCA 60 ± 13 106 ± 33 0.21 0.64
TLCA <LLOQ <LLOQ - -
TLCAS <LLOQ <LLOQ - -
TMCA (α + β) <LLOQ <LLOQ - -
TUDCA <LLOQ <LLOQ 0.40 -
UDCA 206 ± 125 101 ± 25 0.31 0.52
Concentrations presented are nM (mean ± SEM). <LOD = Below the limit of detection. <LLOQ = Below the lower
limit of quantification. ROC = Receiver operating characteristic. Significant p-values are in bold.
2.2. Bile Acid Levels in Mouse Plasma
Of the 22 bile acids screened, 14 were quantifiable in mouse plasma. Only CA and HDCA were
significantly different between APP/PS1 and WT mice (Table 2). In 6-month-old APP/PS1 mice we
detected higher CA (1811 ± 368 nM vs. 10510 ± 4498 nM; p = 0.05), however this was not apparent
at 12 months. Similarly, we detected a significant decrease in HDCA in 12-month-old APP/PS1 mice
which was not evident at 6 months of age (1009 ± 226 nM vs. 364 ± 192 nM; p = 0.04).
Table 2. Bile acid levels in mouse plasma.
Bile Acid
6 Months 12 Months
Control
(n = 5)
APP/PS1
(n = 5) p-Value ROC
Control
(n = 5)
APP/PS1
(n = 5) p-Value ROC
CA 1811 ± 368 10510 ± 4498 0.05 0.80 2934 ± 1247 2099 ± 763 0.45 0.52
CDCA 142 ± 44 392 ± 189 0.18 0.68 300 ± 66 197 ± 90 0.17 0.68
DCA 970 ± 331 3799 ± 2247 0.08 0.80 1569 ± 431 1642 ± 422 0.37 0.52
GCA <LLOQ <LLOQ 0.19 - <LLOQ <LLOQ - -
GCDCA <LOD <LOD - - <LOD <LOD - -
GDCA <LOD <LOD - - <LOD <LOD - -
GLCA <LOD <LOD - - <LOD <LOD - -
GLCAS <LLOQ <LLOQ - - <LLOQ <LLOQ - -
GUDCA <LLOQ <LLOQ - - <LLOQ <LLOQ - -
HDCA 609 ± 214 405 ± 125 0.20 0.64 1009 ± 226 364 ± 192 0.04 0.87
LCA 40 ± 10 64 ± 32 0.32 0.56 77 ± 15 88 ± 32 0.48 0.52
α-MCA 88 ± 50 211 ± 103 0.13 0.65 391 ± 176 136 ± 73 0.37 0.72
β-MCA 3132 ± 977 8780 ± 3781 0.10 0.76 4271 ± 1706 4716 ± 1258 0.30 0.60
Ω-MCA 3068 ± 1035 5246 ± 2189 0.24 0.68 2368 ± 1213 1235 ± 332 0.42 0.52
TCA 865 ± 251 9473 ± 9007 0.36 0.60 1258 ± 244 1051 ± 331 0.31 0.53
TCDCA 52 ± 10 610 ± 575 0.36 0.58 87 ± 15 68 ± 17 0.18 0.70
TDCA 143 ± 40 912 ± 822 0.34 0.52 159 ± 11 188 ± 43 0.40 0.60
TLCA <LLOQ <LLOQ - - <LLOQ <LLOQ - -
TLCAS <LLOQ <LLOQ - - <LLOQ <LLOQ - -
TMCA (α + β) 1529 ± 322 5406 ± 4260 0.38 0.52 1326 ± 318 1408 ± 384 0.44 0.52
TUDCA 347 ± 72 1723 ± 1582 0.42 0.68 990 ± 437 513 ± 221 0.22 0.76
UDCA 363 ± 150 1348 ± 784 0.10 0.72 693 ± 179 838 ± 287 0.26 0.52
Concentrations presented are nM (mean ± SEM). <LOD = Below the limit of detection. <LLOQ = Below the lower
limit of quantification. ROC = Receiver operating characteristic. Significant p-values are in bold.
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2.3. Bile Acid Levels in Human Brain
Of the 22 bile acids screened, only 11 were quantifiable in the human brain specimens analysed.
Only TCA was significantly different in AD cases (Table 3). In samples with AD pathology, TCA
was significantly lower (0.01 ± 0.006 nmol/g vs. 0.06 ± 0.02 nmol/g; P = 0.01) than in age-matched
control subjects.
Table 3. Bile acid levels in human brain tissue.
Bile Acid Control (n = 10) AD (n = 10) p-Value
CA 0.16 ± 0.04 0.24 ± 0.1 0.39
CDCA 0.33 ± 0.11 0.65 ± 0.32 0.41
DCA 0.37 ± 0.11 1.84 ± 1.39 0.47
GCA 0.13 ± 0.03 0.10 ± 0.02 0.25
GCDCA 0.19 ± 0.08 0.14 ± 0.05 0.49
GDCA 0.06 ± 0.02 0.10 ± 0.04 0.46
GLCA <LOD <LOD -
GLCAS <LLOQ <LLOQ -
GUDCA <LLOQ <LLOQ -
HDCA <LLOQ <LLOQ -
LCA 0.06 ± 0.02 0.05 ± 0.01 0.44
α-MCA <LOD <LOD -
β-MCA <LOD <LOD -
Ω-MCA <LLOQ <LLOQ -
TCA 0.06 ± 0.02 0.01 ± 0.006 0.01
TCDCA 0.11 ± 0.03 0.04 ± 0.01 0.07
TDCA <LLOQ <LLOQ -
TLCA <LOD <LOD -
TLCAS <LOD <LOD -
TMCA (α + β) <LOD <LOD -
TUDCA <LOD <LOD -
UDCA 0.06 ± 0.01 0.16 ± 0.09 0.31
Concentrations presented are nmol/g (mean ± SEM). <LOD = Below the limit of detection. <LLOQ = Below the
lower limit of quantification. Significant p-values are in bold.
2.4. Bile Acid Levels in Mouse Brain
Of the 22 bile acids screened, only 8 were quantifiable in mouse brain tissue. At 6 months of age,
only 2 bile acids were significantly different, however, at 12 months a total of 6 bile acids differed
between APP/PS1 and WT mice (Table 4). In 6-month-old APP/PS1 mice we detected higher brain
LCA (0.04 ± 0.01 nmol/g vs. 0.01 ± 0.01 nmol/g; p = 0.05) and lower TMCA (0.08 ± 0.03 nmol/g
vs. 0.14 ± 0.02 nmol/g; p = 0.05). TMCA was also decreased in 12 month old APP/PS1 mice
(0.04 ± 0.01 nmol/g vrs; 0.25 ± 0.07 nmol/g; p = 0.002) along with 5 others: CA (0.08 ± 0.02 nmol/g vs.
0.28 ± 0.08 nmol/g; p = 0.02), β-MCA (0.08 ± 0.04 nmol/g vs. 0.24 ± 0.06 nmol/g; p = 0.02), Ω-MCA
(0.03± 0.01 nmol/g vs. 0.08± 0.02 nmol/g; p = 0.05), TCA (0.04± 0.02 nmol/g vs. 0.16± 0.07 nmol/g;
p = 0.04), and TUDCA (0.01 ± 0.0.001 nmol/g vs 0.03 ± 0.01 nmol/g; p = 0.02).
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Table 4. Bile acid levels in mouse brain.
Bile Acid
6 Months 12 Months
Control
(n = 5)
APP/PS1
(n = 5) p-Value
Control
(n = 5)
APP/PS1
(n = 5) p-Value
CA 0.09 ± 0.01 0.10 ± 0.02 0.47 0.28 ± 0.08 0.08 ± 0.02 0.02
CDCA <LOD <LOD - <LOD <LOD -
DCA 0.07 ± 0.01 0.09 ± 0.02 0.35 0.05 ± 0.003 0.04 ± 0.01 0.17
GCA <LOD <LOD - <LOD <LOD -
GCDCA <LLOQ <LLOQ - <LLOQ <LLOQ -
GDCA <LOD <LOD - <LOD <LOD -
GLCA <LOD <LOD - <LOD <LOD -
GLCAS <LOD <LOD - <LOD <LOD -
GUDCA <LOD <LOD - <LOD <LOD -
HDCA <LOD <LOD - <LOD <LOD -
LCA 0.01 ± 0.01 0.04 ± 0.01 0.05 0.04 ± 0.01 0.05 ± 0.02 0.47
α-MCA <LOD <LOD - <LOD <LOD -
β-MCA 0.08 ± 0.02 0.07 ± 0.02 0.37 0.24 ± 0.06 0.08 ± 0.04 0.02
Ω-MCA 0.05 ± 0.01 0.03 ± 0.01 0.22 0.08 ± 0.02 0.03 ± 0.01 0.05
TCA 0.10 ± 0.03 0.06 ± 0.03 0.11 0.16 ± 0.07 0.04 ± 0.02 0.04
TCDCA <LOD <LOD - <LOD <LOD -
TDCA <LOD <LOD - <LOD <LOD -
TLCA <LOD <LOD - <LOD <LOD -
TLCAS <LOD <LOD - <LOD <LOD -
TMCA (α + β) 0.14 ± 0.02 0.08 ± 0.03 0.05 0.25 ± 0.07 0.04 ± 0.01 0.002
TUDCA 0.02 ± 0.01 0.02 ± 0.002 0.33 0.03 ± 0.01 0.01 ± 0.001 0.02
UDCA <LOD <LOD - <LOD <LOD -
Concentrations presented are nmol/g (mean ± SEM). <LOD = Below the limit of detection. <LLOQ = Below the
lower limit of quantification. Significant p-values are in bold.
3. Discussion
This pilot study employed a targeted LC-MS/MS metabolomics methodology to profile 22 bile
acids in blood plasma from AD patients and human brain specimens of pathologically confirmed cases
of AD. We also profiled blood plasma and brain tissue from APP/PS1 mice with ‘early’ (6 months) and
“late” (12 months) AD-like pathology. This is the first metabolomic study to focus exclusively on bile
acid changes in AD, including the study of these in brain, either in human AD or in an experimental
model of AD.
A non-targeted investigation by Olazaran et al. found plasma bile acid disturbances in persons
with amnestic MCI and AD, including changes in DCA, LCA, and GDCA [6]. In both amnestic MCI
and AD, these 3 bile acids were increased [6]. Significant increases in the levels of the secondary bile
acid GUDCA were reported in the plasma of AD patients [7]. However, in the present study none
of these bile acids were elevated in human plasma from AD patients. Only one bile acid, CA, was
significantly lower in AD patients than in age-matched control subjects. CA was also disturbed in
plasma and brain from APP/PS1 mice. Here we report brain CA to be more than 3-fold lower in the
transgenic mouse than in the WT, but, in contrast, plasma CA was significantly higher.
The APPswe/PS1deltaE9 (APP/PS1) double transgenic mouse has been extensively employed
in AD research for a number of years. The model develops detectable Aβ plaques in the brain by
5–6 months of age, and the mice display progressive age-related impairments in memory that appear
as early as 7 months [24,25]. Behavioural testing shows that the mice have deficits in their spatial
navigation and in reference learning [26]. When we measured bile acid levels in the brain extracts
from APP/PS1 and WT mice that were 6 months old we only found two disturbances: LCA, which
more than doubled, and TMCA, that approximately halved. In 12-month-old APP/PS1 mice the
disturbances were more wide-ranging, with a total of 6 bile acids being affected. In all cases the levels
in APP/PS1 mice were lower. TMCA was 6-fold lower, TCA was 4-fold lower, CA, β-MCA, and
Ω-MCA and TUDCA were 3-fold lower.
As expected, we saw differing bile acid profiles between mouse and human samples [26].
For example, HDCA, α-MCA, and β-MCA were all absent in human plasma but present in mouse
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plasma, and there were a host of bile acids that were present in human plasma but absent in mouse.
There were also substantial differences in the concentration ranges of common bile acids. For example,
plasma CA and DCA were substantially higher in mouse plasma than in human plasma. Fewer bile
acids were detectable in brain tissue and those that were detectable were generally observed to be
much lower. As previously stated, there has been very little investigation of the brain levels of bile
acids, and the findings of the present study conflict with a previous report [8]. In the earlier study,
it was reported that CDCA levels in rat brain were approximately 30 times greater than those in
serum [8]. In fact, the opposite was true in the present study, with CDCA being undetectable in mouse
brain. It also was previously reported that CDCA levels were around 30 times higher than CA and
DCA [8], which was also not the case here. This could relate to rat/mouse species differences in bile
acid metabolism [26] and demonstrates the need to elucidate the neurological levels and functions
of these molecules. However, we do note one consistency with the studies of Mano et al. on the rat
brain [8]. They were unable to detect any glycine-conjugated bile acids in rat brain and we found
these to be similarly below the limit of detection in the mouse brain. There are contrasting differences
between human and mice specimens. For example, CA was significantly lower in AD patients’ plasma,
but higher in 6-month-old APP/PS1 mouse plasma. These differences could be explained in a number
of ways. Firstly, APP/PS1 mice exhibit a particular aspect of AD pathology and not the many complex
features of the human disease. The transgenic model is free from the influences and variability caused
by differing medication and dietary habits of humans and this could be a factor. Finally, it is worth
remembering that there are inherent metabolic differences between mice and humans which mean
that they do not possess entirely the same complement of bile acids, and even though both species
produce CA and TCA, the other metabolic pathways could impact on them. TCA was significantly
lower in both the human AD brain and the 12-month-old APP/PS1 mouse brain.
A common feature associated with the measurement of bile acids is the inherently large variances
observed, and this may limit their use as biomarkers, at least in AD [5]. Here, the variances were
particularly large even in the brain that is a largely self-contained and tightly regulated organ. We
observed coefficients of variation as high as 75%. There are a number of extraneous variables that
modulate bile acid levels. Besides the potential variations in their biosynthesis in the liver (which is
impacted by dietary factors and cholesterol metabolism) there is also the much more unpredictable
influence of the gut microbiota that transforms bile acids. Conditions such as dysbiosis (pathological
imbalance in a microbial community) can significantly impair the metabolism of bile acids and may
result in an inability to maintain glucose homeostasis as well as normal cholesterol breakdown and
excretion [27]. Similarly, antibiotic treatment causes levels of secondary bile acids to decrease, whereas
those of primary bile acids increase as a consequence of the modified metabolic activity of the altered
gut microbiome [28]. Bile metabolism is therefore impacted by the gut microbiome and this is difficult
to account for in the present studies. This study was a pilot which has allowed us to rapidly assess
to what extent bile acids are impacted by the development of AD pathology. However, as with
many pilot investigations, there are limitations. Firstly, it was not possible to account for differences
in the medication or diet of the human subjects and this remains a potential confounding factor
in this study. Secondly, ageing also has a profound effect on cholesterol metabolism which could
influence the biosynthesis of bile acids. Thirdly, the relatively small sample size and student’s T-test
that were used in this pilot study may result in false-positives or in over-estimating the magnitude
of changes [29]. It should be acknowledged that applying more stringent statistical approaches
(incorporating false-discovery rates or Bonferroni corrections) to these datasets inevitably lead to a lack
of significant differences. Therefore, key recommendations for future studies investigating correlations
between AD and bile acids should be that they try to mitigate the large variances by greatly increasing
sample size, applying more stringent statistical approaches which reduce type I errors, and controlling
or accounting for the variations in gut microflora, medication, ageing, gender, and diet.
For future research, there also could be merit in examining the C27 bile acid-intermediates which
are poorly characterised compared with the C24 bile acids measured here. In plasma, C27 bile acids
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can exceed the levels of C24 bile acids and, promisingly, there appears to be smaller variations between
individuals [30]. C27 bile acid-intermediates have been measured in the human brain [10]. Interestingly,
the concentrations of the C27 bile acid 7α-hydroxy-3-oxocholest-4-en-26-oic acid change substantially
in CSF following surgery for aneurysmal subarachnoid hemorrhage [31], and the levels of this bile
acid are higher in chronic subdural hematoma [32]. 7α-hydroxy-3-oxocholest-4-en-26-oic acid has
been shown to be the major cholesterol metabolite found in human CSF and an intermediate in the
biosynthesis of other bile acids [4]. C27 bile acid-intermediates are more hydrophobic and potentially
more cytotoxic than C24 products and the examination of these less well-characterised metabolites in
AD could be worthwhile [10].
4. Materials and Methods
4.1. Human Plasma and Post-Mortem Brain Tissue
Plasma samples were obtained from AD patients (n = 10) and healthy age-matched controls
(n = 10) recruited from the Belfast City Hospital memory clinic. The diagnosis of AD was made
using the NINCDS-ADRDA criteria [33]. Plasma was collected in EDTA tubes from individuals using
standard venepuncture procedures. Samples were immediately centrifuged and stored in aliquots at
−80 ◦C until the date of analysis. Subjects were as closely age-matched as possible. Demographic
characteristics are summarised in Table 5. Participant demographics and clinical characteristics are
detailed in Supplementary Table S1.
Table 5. Summary of characteristics for human brain and plasma samples.
Sample type Demographics AD (n = 10) Control (n = 10)
Human Brain
Age (years: mean (sd)) 76.2 (2.3) 74.5 (3.5)
Range (min-max) 71–79 68–80
Gender F:M 5:5 4:6
Human Plasma
Age (years: mean (sd)) 76.3 (5.6) 77.6 (7.5)
Range (min-max) 70–88 66–87
MMSE (mean (sd)) 21.9 (4.8) 29.3 (0.8)
Gender F:M 6:4 5:5
MMSE – Mini-Mental State Examination.
Brain tissue samples (neocortex, Brodmann area 7) were obtained from postmortem confirmed
AD cases (n = 10) and elderly non-demented age-matched control subjects (n = 10). Tissue cases
were geographically spread across the UK (Bristol, Newcastle, and London) and were obtained
through the Brains for Dementia Research (BDR) initiative, a brain bank network funded by ARUK
and co-ordinated from King’s College London. Consent and ethical approval for the use of tissue
was obtained by individual brain banks, all of which are licensed by the Human Tissue Authority.
Demographic characteristics are summarised in Table 5. Participant characteristics such as gender, age,
PM delay, and Braak stage are detailed in Supplementary Table S2.
4.2. Mouse Plasma and Brain Tissue
Founder APPswe/PS1DE9 (APP/PS1) male mice were initially obtained from the Jackson lab
(USA) and bred at the Ulster University. Heterozygous males were bred with wild-type (WT) C57/Bl6
females bought locally (Harlan, UK). APP/PS1and WT mice were housed under identical conditions
and fed the same rodent maintenance diet (14% fat, 32% protein, and 54% carbohydrate; total energy
of 3.0 kcal/g; Harlan). All experiments were licensed by the UK Home Office (project licence number
PPL2734) in accordance with the Animal (scientific procedures) Act of 1986.
APP/PS1 mice are a transgenic C57BL/6J mouse model co-expressing the Swedish mutation
(K595N/M596L) and the deltaE9 PS-1 exon deletion (mutated human presenilin-1). Offspring were
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tail-snipped and genotyped using PCR. PCR used primers specific for the APP sequence (Forward
“GAATTCCGACATGACTCAGG”, Reverse: “GTTCTGCTGCATCTTGGACA”). Mice not expressing
the transgene were used as WT controls. Female APP/PS1dE9 mice, aged 6 and 12 months and
age-matched WT female C57BL/6J littermate controls (n = 5) were used. Mice were fasted for 16 h
and blood samples were collected into heparinised tubes, centrifuged for 30 seconds at 13,000× g and
the resulting plasma were stored at −80 ◦C prior to metabolomics investigations. Mice were deeply
anaesthetised with pentobarbitol and whole mouse brain was also collected and snap-frozen in liquid
nitrogen and stored at −80 ◦C until further use.
4.3. Brain Tissue Extraction
The extraction method applied to the samples was identical to our previously published
work [22] using Biocrates p180 kits and based upon previous optimisation work undertaken by
others [34]. Both human brain and mouse brain samples were collected into individual tubes to avoid
cross-contamination, lyophilized, and cryogenically milled to a fine powder. 30 mg (± 0.5 mg) of
powdered human PM brain tissue and 15 mg (± 0.5 mg) of powdered mouse brain tissue were weighed
and extracted in 100 µL and 50 µL of solvent (85% ethanol and 15% PBS buffer) respectively in a 1.5 mL
sterile Eppendorf tube. The samples were shaken (10 min), sonicated (15 min), and centrifuged at
(10,000× g; 4 ◦C; 5 min) and the supernatant retained for analysis.
4.4. Bile Acid Quantifications
Quantification of bile acids in both brain tissue extract and plasma were performed using the
Biocrates Bile Acids kit (BIOCRATES, Life Science AG, Innsbruck, Austria). The bile acid kit provides
simultaneous quantification of 22 bile acids (properties outlined in Table 6). Samples were processed
according to the manufacturer’s instructions. Seven calibration standards and a mixture of 10 internal
standards are integrated into this kit and three human plasma based quality controls were applied
to assess the reproducibility of the assay. Briefly, 10 µL of calibrators, quality controls, plasma
samples, and PM brain extracts (prepared as described above) were applied to a 96-well filter plate,
which contains isotopic internal standards. All samples were subsequently extracted in methanol
(100 µL), diluted with water (60 µL), and analysed using a Waters Acquity UPLC system (Milford, MA,
USA) coupled to a triple-quadrupole mass spectrometer (Xevo TQ-S, Waters Corporation, Milford,
MA, USA) operating in multiple reaction monitoring (MRM) mode. Metabolite concentrations were
calculated with plasma concentrations expressed as nM, and brain expressed as nmol per gram of dry
tissue weight.
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Table 6. Bile acids measured in this study.
Bile Acid Abbreviation Empirical Formula Molecular Mass IUPAC Name
1 Cholic acid CA C24H40O5 408.57 (3α,5β,7α,12α)-3,7,12-Trihydroxycholan-24-oic acid
2 Chenodeoxycholic acid CDCA C24H40O4 392.57 (3α,5β,7α,8ξ)-3,7-Dihydroxycholan-24-oic acid
3 Deoxycholic acid DCA C24H40O4 392.57 (3α,5β,12α)-3,12-Dihydroxycholan-24-oic acid
4 Glycocholic acid GCA C26H43NO6 465.62 (3α,5β,7α,8ξ,12α,20R,24Z)-3,7,12,24-Tetrahydroxycholan-24-ylidene]glycine
5 Glycochenodeoxycholic acid GCDCA C26H43NO5 449.62 (3α,5β,7α,8ξ,20R,24Z)-3,7,24-Trihydroxycholan-24-ylidene]glycine
6 Glycodeoxycholic acid GDCA C26H43NO5 449.62 (3α,5β,12α,20R,24Z)-3,12,24-Trihydroxycholan-24-ylidene]glycine
7 Glycolithocholic acid GLCA C26H43NO4 433.62 3α-hydroxy-5β–cholan-24-oylglycine
8 Glycolithocholic acid sulphate GLCAS C26H42NO7S 512.27 3α-hydroxy-5β-cholan-24-oyl)-glycine 3-sulphate
9 Glycoursodeoxycholic acid GUDCA C26H43NO5 449.31 3α,7β-dihydroxy-5β–cholan-24-oylglycine
10 Hyodeoxycholic acid HDCA C24H40O4 392.57 (3α,5β,6α)-3,6-Dihydroxycholan-24-oic acid
11 Lithocholic acid LCA C24H40O3 376.57 (3α,5β)-3-Hydroxycholan-24-oic acid
12 α-muricholic acid α-MCA C24H40O5 408.57 (3α,5β,6β,7α)-3,6,7-Trihydroxycholan-24-oic acid
13 β-muricholic acid β-MCA C24H40O5 408.57 (3α,5β,6β,7β)-3,6,7-Trihydroxycholan-24-oic acid
14 Ω-muricholic acid Ω-MCA C24H40O5 408.57 (3α,5β,6α,7β)-3,6,7-Trihydroxycholan-24-oic acid
15 Taurocholic acid TCA C26H45NO7S 515.70 (3α,5β,7α,8ξ,12α,20R,24Z)-3,7,12-Trihydroxy-N-(2-sulphoethyl)cholan-24-imidic acid
16 Taurochenodesoxycholic acid TCDCA C26H45NO6S 499.70 2-{[(3α,5β,7α,8ξ,9ξ,14ξ)-3,7-Dihydroxy-24-oxocholan-24-yl]amino}ethanesulphonic acid
17 Taurodeoxycholic acid TDCA C26H45NO6S 499.70 α,12α-dihydroxy-5β–cholan-24-oyltaurine
18 Taurolithocholic acid TLCA C26H45NO5S 483.70 (3α,5β,20R,24Z)-3-Hydroxy-N-(2-sulphoethyl)cholan-24-imidic acid
19 Taurolithocholic acid sulphate TLCAS C26H45NO8S2 563.76 (3α,5β,20R,24Z)-N-(2-Sulphoethyl)-3-(sulphooxy)cholan-24-imidic acid
20 Tauromuricholic acid (α and β) TMCA (α + β) C26H45NO7S 515.70 3α,6β,7α/β -trihydroxy-5β–cholan-24-oyltaurine
21 Tauroursodeoxycholic acid TUDCA C26H45NO6S 499.70 2-{[(3α,5β,7β)-3,7-Dihydroxy-24-oxocholan-24-yl]amino}ethanesulphonic acid
22 Ursodeoxycholic acid UDCA C24H40O4 392.57 (3α,5β,7β)-3,7-Dihydroxycholan-24-oic acid
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5. Statistical Analysis
Results are expressed as mean ± SEM. For statistical analysis, bile acid data were normalised
by logarithmic 10 (log 10) transformation, confirmed as normally distributed (Shapiro-Wilk Test,
SPPS version 20) and compared by one-way homoscedastic Student’s T-test (Microsoft Excel, 2013).
Differences were deemed to be significant if p ≤ 0.05). A Venn diagram was compiled (Figure 1) to
summarise the differences observed. Receiver operating characteristic (ROC) analysis was performed
using online metabolomics tools Metaboanalyst v 3.0 [35].
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